The Long Term Suppression of Experimental Autoimmune Encephalomyelitis by the Opioid Growth Factor and Low Dose Naltrexone

The FASEB Journal
01 April 2011
https://doi.org/10.1096/fasebj.25.1_supplement.677.6 

Intermittent blockade of OGFr and treatment of autoimmune disorders

Exp Biol Med (Maywood)
December 2018
https://pubmed.ncbi.nlm.nih.gov/30541348/

Enhancing acupuncture by low dose naltrexone

LDN MS and Me - Chris from the UK (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Neurologist Dr Gary Thomas talks about Low Dose Naltrexone (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis

BMC Immunol
24 April 2015
https://pubmed.ncbi.nlm.nih.gov/25906771/

Duration of opioid receptor blockade determines biotherapeutic response

J Clin Gastroenterol
October 2015
https://pubmed.ncbi.nlm.nih.gov/26119823/

Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability

J Clin Gastroenterol
October 2015
https://pubmed.ncbi.nlm.nih.gov/26203498/

Treatment of clinically isolated syndrome with Low Dose Naltrexone

Clin Case Rep Rev
January 2015
http://www.oatext.com/pdf/CCRR-1-161.pdf

Opioid growth factor and low dose naltrexone impair central nervous system infiltration by CD4+T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis

Exp Biol Med (Maywood)
January 2016
http://www.ncbi.nlm.nih.gov/pubmed/26202376